Market Currents
Seattle Genetics (SGEN +4%) pops after Needham raises its price target for the shares to $25...
-
Friday, June 8, 2012, 11:54 AM ETSeattle Genetics (SGEN +4%) pops after Needham raises its price target for the shares to $25 from $20, citing positive data presented at ASCO regarding the company's ongoing Adcetris clinical trials. Needham believes the company may succeed in adding re-treatment to the drug's label later this year, and thinks it will fill an important role in future oncology procedures.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
